Alström syndrome is a progressive multisystemic hereditary disease, of autosomal recessive inheritance, caused by biallelic variants in the ALMS1 gene. The alteration of this protein associated with centrosomes and primary cilia causes a ciliopathy with progressive visual and auditory impairment, childhood obesity, insulin resistance, type 2 diabetes mellitus, and cardiac, hepatic, and renal dysfunction.
Alström syndrome
The ALMS1 gene encodes a large protein mainly located in the centrosomes and basal bodies of primary cilia. These structures act as cell signaling platforms and participate in intracellular transport, cytoskeleton organization, and the response of various tissues to metabolic and developmental signals. Therefore, the function of ALMS1 is particularly relevant in organs with high functional demand, such as the retina, inner ear, heart, liver, kidney, and metabolic tissues.
Pathogenic variants in ALMS1 typically result in loss of protein function and alter the biology of primary cilia, leading to a progressive multisystem disorder. The most characteristic manifestations include cone-rod dystrophy, sensorineural hearing loss, childhood obesity, marked insulin resistance, and progressive fibrosis in organs such as the liver, kidney, lung, and myocardium. The disease is inherited in an autosomal recessive manner, meaning an affected person must inherit two altered copies of the gene, one from each parent. It is an ultrarare disorder, with fewer than 1,000 cases described in the world literature and an estimated incidence of approximately 1 in every 100,000 to 1,000,000 live births. It affects people of different ethnic backgrounds and shows considerable clinical variability.
Symptoms
The onset of Alström syndrome typically occurs within the first few months of life. Cone-rod dystrophy causes nystagmus, photophobia, and progressive vision loss, often to legal blindness in infancy or adolescence. Bilateral sensorineural hearing loss develops gradually, and childhood obesity is associated with insulin resistance, hypertriglyceridemia, and early-onset type 2 diabetes. Dilated cardiomyopathy in infancy or later restrictive/dilated cardiomyopathy, fatty liver disease, liver fibrosis, progressive renal dysfunction, endocrine abnormalities, and respiratory complications may also occur. Cognitive development is usually preserved, although some patients have mild developmental delays or learning difficulties.
Disease management
There is no curative treatment for Alström syndrome, so management is based on early detection and multidisciplinary follow-up of complications. Periodic ophthalmological, audiological, cardiological, endocrinological, hepatic, and renal check-ups are recommended, along with nutritional support, adapted physical activity, and management of obesity, insulin resistance, diabetes, and dyslipidemia. Cardiac and renal involvement is treated with standard measures according to clinical severity. Visual and hearing loss requires low vision aids, educational adaptation, hearing aids, or cochlear implants when indicated. The main objective is to anticipate complications, maintain functionality, and improve quality of life.
Genes analyzed
Bibliography
Paisey RB, Steeds R, Barrett T, et al. Alström Syndrome. 2003 Feb 7 [updated 2019 Jun 13]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Tahani N, Maffei P, Dollfus H, et al. Consensus clinical management guidelines for Alström syndrome. Orphanet J Rare Dis. 2020 Sep 21;15(1):253.
Bea-Mascato B, Valverde D. Genotype-phenotype associations in Alström syndrome: a systematic review and meta-analysis. J Med Genet. 2023 Dec 21;61(1):18-26.
